Drug Susceptibility Testing of
            <i>Mycobacterium tuberculosis</i>
            Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method

Klingeren, B. Van; Dessens-Kroon, M.; Laan, Tridia van der; Kremer, Kristin; Soolingen, Dick van

doi:10.1128/jcm.00244-07

Cited by 92 publications

(86 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Susceptibility testing was performed using the Middlebrook 7H10 agar dilution method (van Klingeren et al, 2007). We tested susceptibility to rifampicin, rifabutin, isoniazid, ethambutol, streptomycin, amikacin, clarithromycin, ciprofloxacin, moxifloxacin, cycloserine, prothionamide, clofazimine and linezolid.…”

Section: Case Reportsmentioning

confidence: 99%

Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species

Ingen

Lindeboom

Hartwig

et al. 2009

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLO

View full text Add to dashboard Cite

Slowly growing, scotochromogenic bacteria of a novel Mycobacterium species were isolated from lymph node samples in two children and pulmonary samples in two elderly patients from different regions in the Netherlands as well as from a surface water sample in Zambia. Its 16S rRNA gene, 16S-23S internal transcribed spacer (ITS), hsp65 and rpoB gene sequences are unique in comparison with other mycobacteria. Phylogenetic analysis based on the 16S rRNA gene sequence revealed that these micro-organisms are most closely related to Mycobacterium scrofulaceum ATCC 19981 T (8 differences; 0.6 % divergence). The hsp65 sequence shows 96 % similarity to that of Mycobacterium saskatchewanense MB54784 and the rpoB sequence shows 95 % similarity to that of Mycobacterium chimaera CIP 107892 T . The 16S-23S ITS sequence places these micro-organisms within the Mycobacterium avium complex, as a novel ITS sequevar. This is not supported by analysis of the 16S rRNA, hsp65 or rpoB gene sequences. Their scotochromogenicity, combined with mostly positive urease, positive semiquantitative catalase and negative tellurite reduction tests, set these isolates apart from related species. The mycolic acid patterns, obtained by HPLC, are similar to that of Mycobacterium scrofulaceum, though the peak heights and distribution present minor differences. We propose the name Mycobacterium mantenii sp. nov. for this novel species. The type strain, isolated from a lymph node biopsy sample, is strain 04-1474 T (5NLA000401474 T 5CIP 109863 T 5DSM 45255 T ).

show abstract

Section: Case Reportsmentioning

confidence: 99%

Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species

Ingen

Lindeboom

Hartwig

et al. 2009

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLO

View full text Add to dashboard Cite

show abstract

“…Susceptibility testing was performed by using an agar dilution method (13). Drugs in the susceptibility testing panel were isoniazid, rifampin, ethambutol, streptomycin, cycloserine, prothionamide, amikacin, ciprofl oxacin, clofazimine, clarithromycin, and rifabutin.…”

Section: Mycobacterium Xenopi Clinical Relevance and Determinants Thmentioning

confidence: 99%

Mycobacterium xenopiClinical Relevance and Determinants, the Netherlands

Ingen

Boeree

Lange

et al. 2008

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

In the Netherlands, isolation of Mycobacterium xenopi is infrequent, and its clinical relevance is often uncertain. To determine clinical relevance and determinants, we retrospectively reviewed medical fi les of all patients in the Netherlands in whom M. xenopi was isolated from January 1999 through March 2005 by using diagnostic criteria for nontuberculous mycobacterial infection published by the American Thoracic Society. We found 49 patients, mostly white men, with an average age of 60 years and pre-existing pulmonary disease; of these patients, 25 (51%) met the diagnostic criteria. Mycobacterial genotype, based on 16S rRNA gene sequencing, was associated with true infection. Most infections were pulmonary, but pleural and spinal infections (spinal in HIV-infected patients) were also noted. Treatment regimens varied in content and duration; some patients were overtreated and some were undertreated. M ycobacterium xenopi was fi rst described by Schwabacher in 1959; it was isolated from skin lesions in a clawed frog and named after the offi cial species designation of the frog, Xenopus laevis (1). Thereafter, these slowgrowing mycobacteria have been recovered from heated water systems in many countries and more recently from natural waters in Finland (2). Transmission to humans is believed to originate from the environment, through aerosol inhalation or ingestion. Human-to-human transmission and transmission from animal reservoirs remain controversial because these routes have not been proven by molecular typing (3,4).Pulmonary M. xenopi infections are most common, but extrapulmonary and disseminated infections have also been recorded (5,6). A predisposing factor is impaired immunity, either local (e.g., pre-existing pulmonary disease) or systemic (e.g., hematologic malignancy, immunosuppressive medication, or HIV/AIDS) (5,7).Its survival in fl owing water systems and resistance to common disinfectants enables M. xenopi to contaminate laboratory samples and medical devices such as bronchoscopes, thus causing healthcare-acquired (pseudo) infections and laboratory cross-contaminations (3,6,8,9). Differentiating true infection from pseudoinfection is of paramount importance because treatment of M. xenopi infections is time-consuming and often complicated. The British Thoracic Society (BTS) trial in 2001 established that treatment for pulmonary infections should consist of a 2-year course of rifampin and ethambutol; regimens including macrolides or fl uoroquinolones are still being investigated (10). The American Thoracic Society (ATS) established general criteria for the diagnosis and treatment of nontuberculous mycobacterial, not specifi cally M. xenopi, infections. The treatment guidelines are similar to those by the BTS, although the ATS guidelines advocate macrolidecontaining regimens (5).To assess frequency and clinical relevance of M. xenopi isolation and its determinants in the Netherlands, we performed a retrospective case study. We used the ATS diagnostic criteria available during the study period to diff...

show abstract

“…Susceptibility testing was performed for eleven of the novel isolates from eleven patients using the agar dilution method (van Klingeren et al, 2007). For the novel isolates, we recorded in vitro resistance to rifampicin (MIC 2 mg l 21 ), resistance or intermediate susceptibility to ethambutol (MIC 10-20 mg l 21 ) and intermediate susceptibility to isoniazid (MIC 0.5-1 mg l 21 ).…”

mentioning

confidence: 99%

Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients

Ingen¹,

Boeree²,

Lange³

et al. 2009

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLO

View full text Add to dashboard Cite

Eighteen isolates of a nonchromogenic, slowly growing, non-tuberculous species of the genus Mycobacterium were cultured from respiratory specimens obtained over the last eight years from 17 patients in the Netherlands. These isolates were grouped because they revealed a unique 16S rRNA gene sequence and were related to Mycobacterium xenopi. None of the 17 patients met the American Thoracic Society diagnostic criteria for non-tuberculous mycobacterial disease, which distinguishes the novel isolates from the related species, M. xenopi. A polyphasic taxonomic approach, including identification by biochemical and phenotypical analysis, hsp65 gene sequencing and PCR restriction enzyme pattern analysis, and sequence analyses of the rpoB gene and 16S-23S internal transcribed spacer supported the separate species status of the novel isolates. The name Mycobacterium noviomagense sp. nov. is proposed for the novel strains. The type strain is NLA000500338 T (5DSM 45145 T 5CIP 109766 T ). A more distinctive taxonomy of NTM is a prerequisite for the assessment of their clinical relevance.

show abstract

Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method

Cited by 92 publications

References 21 publications

Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species

Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species

Mycobacterium xenopiClinical Relevance and Determinants, the Netherlands

Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients

Contact Info

Product

Resources

About